Ramalingam Expands on Osimertinib Updates in NCCN Guidelines for EGFR+ NSCLC

November 13, 2017 – The National Comprehensive Cancer Network (NCCN) unveiled its latest treatment guidelines for patients with varying histologies of non–small cell cancer (NSCLC), including those who are EGFR-mutation positive.1 One of the notable updates in this area, explained Suresh A. Ramalingam, MD, is the category 2A recommendation to give osimertinib, a third-generation irreversible EGFR inhibitor designed to inhibit both EGFR-sensitizing and … (leggi tutto)